NCT06503458View on ClinicalTrials.gov

A Low-Interventional Study of an Electronic Sickle Cell Disease Patient Reported Outcomes in Sickle Cell Participants

TerminatedOBSERVATIONAL
Enrollment

52

Participants

Timeline

Start Date

January 19, 2022

Primary Completion Date

December 23, 2023

Study Completion Date

April 10, 2024

Conditions
Sickle Cell DiseaseSickle Cell Anemia
Trial Locations (1)

01801

Sanguine Biosciences, Woburn

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

Sanguine Biosciences

INDUSTRY

NCT06503458 - A Low-Interventional Study of an Electronic Sickle Cell Disease Patient Reported Outcomes in Sickle Cell Participants | Biotech Hunter | Biotech Hunter